These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30023075)

  • 1. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice.
    Al Mansari A; Obeid Y; Islam N; Fariduddin M; Hassoun A; Djaballah K; Malek M; Dicker D; Chaudhury T
    BMJ Open Diabetes Res Care; 2018; 6(1):e000519. PubMed ID: 30023075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes.
    Miyoshi H; Baxter M; Kimura T; Hattori M; Morimoto Y; Marinkovich D; Tamiwa M; Hirose T
    Diabetes Ther; 2021 May; 12(5):1341-1357. PubMed ID: 33730337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice.
    Hidvégi T; Balogh Z; Vass V; Kovács G; Stella P
    Diabetes Ther; 2020 Feb; 11(2):467-478. PubMed ID: 31901115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA.
    Rattelman CR; Ciemins EL; Stempniewicz N; Mocarski M; Ganguly R; Cuddeback JK
    Diabetes Ther; 2021 Feb; 12(2):581-594. PubMed ID: 33460018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan.
    Ikeda Y; Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Jun; 7(2):188-198. PubMed ID: 30603263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes.
    Fahrbach J; Jacober S; Jiang H; Martin S
    J Diabetes Sci Technol; 2008 Sep; 2(5):831-8. PubMed ID: 19885269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study.
    Bu S; Zhang X; Zhu H; Shuai Y; Xing X; Yang W;
    Diabetes Ther; 2017 Aug; 8(4):887-898. PubMed ID: 28623551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study).
    Brož J; Janíčková Žďárská D; Urbanová J; Piťhová P; Doničová V; Pálová S; Pelechová B; Smržová A; Kvapil M
    Diabetes Ther; 2021 Jul; 12(7):1799-1808. PubMed ID: 34028699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes.
    Zhang Y; Xie YJ; Meng DD; Zhang HH; Chen H; Liu E
    Diabetol Metab Syndr; 2014 Mar; 6(1):37. PubMed ID: 24620742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China.
    Chen M; Zhang P; Zhao Y; Duolikun N; Ji L
    Diabetes Metab Syndr Obes; 2022; 15():3375-3385. PubMed ID: 36341227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
    Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
    Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy.
    Chou WY; Li YR; Chan WK; Chen ST
    Biomed J; 2018 Dec; 41(6):348-355. PubMed ID: 30709576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.